The overall goal of the University of Pennsylvania Udall Center is to address the problem of cognitive impairment in Parkinson's Disease (PD) from bench to bedside. This project contributes to that goal by developing a disease-specific rating scale to measure the impact that cognitive impairment has on daily function. The scale would be appropriate for use in patients with PD and dementia (PDD) and also for patients with PD and cognitive impairments not sufficient to meet diagnostic criteria for PDD. Our proposed rating scale is intended to be an outcome measure for observational studies and clinical trials. There is currently no disease-specific scale to address the impact that cognitive impairment has on daily function in PD, and clinical trials to date have borrowed functional measures developed for use in Alzheimer's disease (AD). However, the cognitive profile of patients with PD is distinct from AD. In addition, patients with PD have motor impairments that affect their daily, function, and may obscure the impact of cognitive impairment as measured by existing scales used in dementia research. Thus, there is a need for a functional rating scale specifically for use in PD patients with cognitive impairment. We propose to develop a new scale, the """"""""Functional Consequences of Cognitive Impairment"""""""" (FCCI) scale to address this unmet need. We will take a methodologically rigorous approach to scale development beginning with detailed qualitative studies to generate scale items, followed by psychometric studies to demonstrate the reliability and validity of the FCCI.
The first aim of this study is to conduct qualitative studies involving patients and knowledgeable informants to generate a range of items addressing the functional consequence of cognitive impairment that will be used to create the final rating scale.
The second aim of this study is to undertake detailed psychometric testing of the reliability and internal consistency of the FCCI.
The third aim i s to assess the validity, test-retest reliability and responsiveness to change of the FCCI in a longitudinal cohort study of patients with PD. The product of our study will be a reliable and valid measure of the impact of cognitive impairmen on basic and instrumental aspects of daily function. We hypothesize that our new instrument will capture the impact of cognitive impairment on daily function to a greater extent than existing scales used in PD and dementia research. Over the course of the project, we will gain valuable insights into the rate of progression of functional impairment in PDD, and the relative contributions of motor and non-motor features of PD to function over time.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS053488-04
Application #
8101870
Study Section
Special Emphasis Panel (ZNS1)
Project Start
Project End
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
4
Fiscal Year
2010
Total Cost
$288,426
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Olm, Christopher A; McMillan, Corey T; Irwin, David J et al. (2018) Longitudinal structural gray matter and white matter MRI changes in presymptomatic progranulin mutation carriers. Neuroimage Clin 19:497-506
Sandelius, Åsa; Portelius, Erik; Källén, Åsa et al. (2018) Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology. Alzheimers Dement :
Henderson, Michael X; Peng, Chao; Trojanowski, John Q et al. (2018) LRRK2 activity does not dramatically alter ?-synuclein pathology in primary neurons. Acta Neuropathol Commun 6:45
Chahine, L M; Dos Santos, C; Fullard, M et al. (2018) Modifiable vascular risk factors, white matter disease and cognition in early Parkinson's disease. Eur J Neurol :
Cousins, Katheryn A Q; Ash, Sharon; Grossman, Murray (2018) Production of verbs related to body movement in amyotrophic lateral sclerosis (ALS) and Parkinson's Disease (PD). Cortex 100:127-139
Guerreiro, Rita; Ross, Owen A; Kun-Rodrigues, Celia et al. (2018) Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurol 17:64-74
Shi, Min; Tang, Lu; Toledo, Jon B et al. (2018) Cerebrospinal fluid ?-synuclein contributes to the differential diagnosis of Alzheimer's disease. Alzheimers Dement 14:1052-1062
Tropea, Thomas F; Xie, Sharon X; Rick, Jacqueline et al. (2018) APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease. Mov Disord 33:289-297
Portelius, Erik; Olsson, Bob; Höglund, Kina et al. (2018) Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathol 136:363-376
Polinski, Nicole K; Volpicelli-Daley, Laura A; Sortwell, Caryl E et al. (2018) Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents. J Parkinsons Dis 8:303-322

Showing the most recent 10 out of 339 publications